Exenatide use in islet transplantation-reasons to remain optimistic

Transplantation

Volumn 87, Issue 1, 2009, Pages 154-

  Froud, Tatiana ^a   Ricordi, Camillo ^a   Alejandro, Rodolfo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; INSULIN; SITAGLIPTIN;

CLINICAL RESEARCH; DRUG SAFETY; DRUG USE; GRAFT DYSFUNCTION; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; LETTER; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

EID: 66149129139     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318191ebe9     Document Type: Letter

References (2)

1. Froud T, Faradji RN, Tharavanij T, et al. Long term insulin independence and restoration of first phase insulin release after supplemental islet infusion under exenatide treatment in subjects with islet graft dysfunction. Transplantation 2008; 86(2S) abstract number 245.
2. Cechin SR, Perez-Alvarez I, Ochoa MS, et al. Ex-enatide (Byetta) activates anti-inflammatory and anti-apoptotic pathways in human pancreatic islets. Diabetes 2008; 57(S1): A466, abstract number 1678-P.